Internal Medicine, Hematology · Salt Lake City, UT
NPI
1972742245
Since 2009
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
University of Utah Hospital, 50 North Medical Drive
Salt Lake City, UT, 84132
Phone (801) 581-2121
Groups this clinician bills Medicare through
Medicare paid, 2024
$41K
769 services
Medicare patients, 2024
149
Average age 73
Drug cost, 2024
$5.9M
903 prescriptions
Company payments, 2025
$12K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Srinivas K Tantravahi was code G0316 (prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th), 197 times for 26 patients. In total Srinivas K Tantravahi billed 769 services in 14 codes, and Medicare paid $41K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-16.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G0316 Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 197 | 26 | $23.17 | $4,565 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 166 | 95 | $12.64 | $2,098 |
| 99214 Office E&M - Established | Facility | 161 | 90 | $69.36 | $11K |
| 99233 Hospital E&M - Subsequent | Facility | 122 | 29 | $91.74 | $11K |
| 99215 Office E&M - Established | Facility | 41 | 28 | $100.07 | $4,103 |
| 99204 Office E&M - New | Facility | 21 | 21 | $98.83 | $2,075 |
| 99223 Hospital E&M - Initial | Facility | 15 | 14 | $130.23 | $1,953 |
| 99239 Hospital Discharge Management | Facility | 14 | 13 | $88.81 | $1,243 |
By year: 2022 $34K for 429 services; 2023 $24K for 305 services; 2024 $41K for 769 services.
Medicare prescription drug claims, 2024
In 2024, the drug Srinivas K Tantravahi prescribed most often to Medicare patients was Acyclovir, with 97 prescriptions and refills. In total Srinivas K Tantravahi wrote 903 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 97 | 123 | 25 | $2,316 |
| Jakafi Ruxolitinib Phosphate | 78 | 78 | Under 11 | $1.3M |
| Hydroxyurea Generic | 58 | 111 | 16 | $1,432 |
| Sprycel Dasatinib | 58 | 66 | 12 | $632K |
| Scemblix Asciminib Hydrochloride | 44 | 55 | Under 11 | $1.6M |
| Iclusig Ponatinib Hcl | 36 | 36 | Under 11 | $767K |
| Levofloxacin Generic | 31 | 33 | 15 | $487 |
| Bosulif Bosutinib | 30 | 30 | Under 11 | $326K |
| Cyclosporine Modified Cyclosporine, Modified | 28 | 38 | Under 11 | $3,213 |
| Imatinib Mesylate Generic | 28 | 28 | Under 11 | $2,502 |
| Venclexta Venetoclax | 24 | 24 | Under 11 | $44K |
| Potassium Chloride Generic | 22 | 22 | Under 11 | $467 |
| Prochlorperazine Maleate Generic | 20 | 24 | Under 11 | $307 |
| Posaconazole Generic | 19 | 19 | Under 11 | $17K |
| Gengraf Cyclosporine, Modified | 18 | 19 | Under 11 | $1,144 |
Brand drugs: 359 claims; generic drugs: 544 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Srinivas K Tantravahi $12K ($7,265 in general payments such as food, travel and fees and $4,953 for research) from 11 companies. The largest payer was Novartis Pharmaceuticals Corporation with $6,914.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.